NICE Request Case for Including Nivolumab (Opdivo, Bristol-Myers Squibb) in the Cancer Drugs Fund (CDF)
NICE’s appraisal committee concluded that nivolumab was not cost-effective for all patients with squamous and non-squamous advanced non-small-cell lung cancer but it did appear to benefit some more than others.
The appraisal committee agreed that it was important to explore this benefit.
The draft guidance is now out for consultation, consultees, including the manufacturer, healthcare professionals and members of the public are now able to comment on the recommendations. It closes on 4 November and you can respond here